Taysha Gene Therapies
TSHA
63 hedge funds and large institutions have $411M invested in Taysha Gene Therapies in 2023 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 14 increasing their positions, 6 reducing their positions, and 11 closing their positions.
4,435% more capital invested
Capital invested by funds: $9.05M → $411M (+$402M)
218% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 11
133% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 6
62% more funds holding
Funds holding: 39 → 63 (+24)
48.17% more ownership
Funds ownership: 21.35% → 69.52% (+48%)
18% more call options, than puts
Call options by funds: $785K | Put options by funds: $663K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$43.7M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$34.5M |
| 3 |
RI
RTW Investments
New York
|
+$31.6M |
| 4 |
VA
VR Adviser
New York
|
+$27M |
| 5 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$20.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.15M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$827K |
| 3 |
LCM
Laurion Capital Management
New York
|
-$775K |
| 4 |
CC
Carlson Capital
Dallas,
Texas
|
-$320K |
| 5 |
Squarepoint
New York
|
-$97.2K |
TSHA Hedge Fund Activity: Q3 2023 in Review
63 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Taysha Gene Therapies (TSHA) for Q3 2023, worth a combined $411M — up 4,435% from $9.05M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new TSHA positions and 11 closed out — a net gain of 24 holders — while 14 added to existing stakes and 6 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $43.7M. The largest seller was Millennium Management, exiting entirely with an estimated $1.15M sold.
- 63 institutional investors held Taysha Gene Therapies (TSHA) as of Q3 2023, up from 39 in Q2 2023.
- Funds reported $411M of Taysha Gene Therapies stock for Q3 2023, up 4,435% quarter-over-quarter.
- 35 funds opened new Taysha Gene Therapies positions in Q3 2023 and 11 closed out, a net change of +24 holders.
- The largest Taysha Gene Therapies buyer in Q3 2023 was Fidelity Investments, an estimated $43.7M added.
- The largest Taysha Gene Therapies seller in Q3 2023 was Millennium Management, an estimated $1.15M sold.
Based on aggregated 13F filings for Q3 2023.